The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: Implications for preventing chemotherapy resistance
Open accessAbstract
Glutamine metabolism is crucial for cancer cell growth via the generation of intermediate molecules in the tricarboxylic acid (TCA) cycle, antioxidants and ammonia. The goal of the current study was to evaluate the effects of glutamine on metabolism in the breast cancer tumor microenvironment, with a focus on autophagy and cell death in both epithelial and stromal compartments. For this purpose, MCF7 breast cancer cells were cultured alone or co-cultured with non-transformed fibroblasts in media containing high glutamine and low glucose (glutamine +) or under control conditions, with no glutamine and high glucose (glutamine -). Here, we show that MCF7 cells maintained in co-culture with glutamine display increased mitochondrial mass, as compared with control conditions. Importantly, treatment with the autophagy inhibitor chloroquine abolishes the glutamine-induced augmentation of mitochondrial mass. It is known that loss of caveolin-1 (Cav-1) expression in fibroblasts is associated with increased autophagy and an aggressive tumor microenvironment. Here, we show that Cav-1 downregulation which occurs in fibroblasts maintained in co-culture specifically requires glutamine. Interestingly, glutamine increases the expression of autophagy markers in fibroblasts, but decreases expression of autophagy markers in MCF7 cells, indicating that glutamine regulates the autophagy program in a compartment-specific manner. Functionally, glutamine protects MCF7 cells against apoptosis, via the upregulation of the anti-apoptotic and anti-autophagic protein TIGAR. Also, we show that glutamine cooperates with stromal fibroblasts to confer tamoxifen-resistance in MCF7 cancer cells. Finally, we provide evidence that co-culture with fibroblasts (1) promotes glutamine catabolism, and (2) decreases glutamine synthesis in MCF7 cancer cells. Taken together, our findings suggest that autophagic fibroblasts may serve as a key source of energy-rich glutamine to fuel cancer cell mitochondrial activity, driving a vicious cycle of catabolism in the tumor stroma and anabolic tumor cell expansion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“Previous studies have shown that the protein TIGAR inhibits glycolysis, apoptosis and autophagy and protects cells from oxidative stress.(42,43) Our findings are consistent with a previous report showing that glutamine-derived ammonia does not alter mitochondrial activity and membrane polarity in the epithelial tumor…”
ResultWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001 · cited 1×
“c-Myc via miR23a/b leads to increased glutaminase activity,(4) and increased expression of glutamine transporters.(44) Also, by increasing glutamine metabolism, c-Myc protects transformed cells from apoptosis.”
BackgroundNutrition Needs of Mammalian Cells in Tissue Culture
Eagle, H. (1955) · Science · doi:10.1126/science.122.3168.501 · Cited by 1,619 · cited 1×
“Also, cancer cells show high glutamine uptake(2) and they metabolize glutamine at a much higher rate than any other aminoacid.(3,4) The mechanism(s) by which glutamine promotes cancer growth are poorly understood.”
BackgroundTargeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Wang, J.-B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L. B., Dias, S. M. G., Dang, C. V., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.009 · Cited by 821
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., & Lazebnik, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703099 · Cited by 690
Lisanti, M. P., Martinez-Outschoorn, U. E., Chiavarina, B., Pavlides, S., Whitaker-Menezes, D., Tsirigos, A., Witkiewicz, A. K., Lin, Z., Balliet, R. M., Howell, A., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.13370 · Cited by 199
Self-citationGlutamine in neoplastic cells: Focus on the expression and roles of glutaminases
Szeliga, M., & Obara-Michlewska, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.01.008 · Cited by 76
Cited by
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)
ZHENG, J. (2012) · Oncology Letters · doi:10.3892/ol.2012.928 · Cited by 963
Metabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P., Huang, S. C.-C., Fendt, S.-M., & Ho, P.-C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 733
Endothelial Cell Metabolism in Normal and Diseased Vasculature
Eelen, G., de Zeeuw, P., Simons, M., & Carmeliet, P. (2015) · Circulation Research · doi:10.1161/circresaha.116.302855 · Cited by 627
Cancer-associated adipocytes: key players in breast cancer progression
Wu, Q., Li, B., Li, Z., Li, J., Sun, S., & Sun, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0778-6 · Cited by 462
Martinez-Outschoorn, U. E., Lisanti, M. P., & Sotgia, F. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.01.005 · Cited by 423
Self-citationTargeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis
Xiang, Y., Stine, Z. E., Xia, J., Lu, Y., O’Connor, R. S., Altman, B. J., Hsieh, A. L., Gouw, A. M., Thomas, A. G., Gao, P., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75836 · Cited by 409
Wilde, L., Roche, M., Domingo-Vidal, M., Tanson, K., Philp, N., Curry, J., & Martinez-Outschoorn, U. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.004 · Cited by 326
Self-citationRole of the tumor microenvironment in tumor progression and the clinical applications (Review)
YUAN, Y., JIANG, Y.-C., SUN, C.-K., & CHEN, Q.-M. (2016) · Oncology Reports · doi:10.3892/or.2016.4660 · Cited by 320
The Warburg Effect 97 Years after Its Discovery
Pascale, R. M., Calvisi, D. F., Simile, M. M., Feo, C. F., & Feo, F. (2020) · Cancers · doi:10.3390/cancers12102819 · Cited by 300
Gong, J., Lin, Y., Zhang, H., Liu, C., Cheng, Z., Yang, X., Zhang, J., Xiao, Y., Sang, N., Qian, X., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2434-z · Cited by 284
Autophagy and mitophagy in cancer metabolic remodelling
Ferro, F., Servais, S., Besson, P., Roger, S., Dumas, J.-F., & Brisson, L. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.029 · Cited by 281
Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
Verbaanderd, C., Maes, H., Schaaf, M. B., Sukhatme, V. P., Pantziarka, P., Sukhatme, V., Agostinis, P., & Bouche, G. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.781 · Cited by 275
De Luca, A., Fiorillo, M., Peiris-Pagès, M., Ozsvari, B., Smith, D. L., Sanchez-Alvarez, R., Martinez-Outschoorn, U. E., Cappello, A. R., Pezzi, V., Lisanti, M. P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4401 · Cited by 259
Self-citationCaveolin-1 in the regulation of cell metabolism: a cancer perspective
Nwosu, Z. C., Ebert, M. P., Dooley, S., & Meyer, C. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0558-7 · Cited by 256
Witkiewicz, A. K., Whitaker-Menezes, D., Dasgupta, A., Philp, N. J., Lin, Z., Gandara, R., Sneddon, S., Martinez-Outschoorn, U. E., Sotgia, F., & Lisanti, M. P. (2012) · Cell Cycle · doi:10.4161/cc.11.6.19530 · Cited by 239
Self-citationOptimization of liquid overlay technique to formulate heterogenic 3D co-cultures models
Costa, E. C., Gaspar, V. M., Coutinho, P., & Correia, I. J. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25210 · Cited by 156
Sun, K., Tang, S., Hou, Y., Xi, L., Chen, Y., Yin, J., Peng, M., Zhao, M., Cui, X., & Liu, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.025 · Cited by 138
Sun, W. Y., Kim, H. M., Jung, W.-H., & Koo, J. S. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0915-8 · Cited by 77
Kefayat, A., Ghahremani, F., Motaghi, H., & Mehrgardi, M. A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.01.037 · Cited by 54
Metadata
- Authors
- Ko, Y.-H., Lin, Z., Flomenberg, N., Pestell, R. G., Howell, A., Sotgia, F., Lisanti, M. P., & Martinez-Outschoorn, U. E.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-12-15
- Volume
- 12
- Issue
- 12
- Pages
- 1085-1097
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W1967418267
- Cited by
- 173
- References
- 8
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.